secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029017
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025
------------------------------------------------------------------------------

- Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.
- Cash, cash equivalents and investments ~$1.2B at Dec 31, 2024, down ~$60M from Sept 30, 2024.
- FDA accepted aficamten NDA with target PDUFA date of September 26, 2025; MAA validated in Europe.
- Topline results from Phase 3 MAPLE-HCM trial expected in Q2 2025.
- 2025 GAAP operating expense guidance: $670M-$710M; non-cash stock comp $110M-$120M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/0000950170-25-029017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/cytk-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer